<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS) is associated with a risk of obstetrical complications, affecting both the mother and the fetus </plain></SENT>
<SENT sid="1" pm="."><plain>Obstetrical APS is defined by a history of three consecutive spontaneous <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> before 10 weeks of gestation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">WG</z:e>), an intra-uterine fetal <z:hpo ids='HP_0011420'>death</z:hpo> after 10 WG, or a <z:hpo ids='HP_0001622'>premature birth</z:hpo> before 34 WG because of severe pre-<z:hpo ids='HP_0100601'>eclampsia</z:hpo>, <z:hpo ids='HP_0100601'>eclampsia</z:hpo> or placental adverse outcomes (<z:hpo ids='HP_0001511'>intrauterine growth retardation</z:hpo>, <z:hpo ids='HP_0001562'>oligohydramnios</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>Pregnancy in women with a diagnosis of obstetric APS is at increased risk for <z:hpo ids='HP_0011419'>placental abruption</z:hpo>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HELLP</z:e> (<z:mp ids='MP_0010163'>Hemolysis</z:mp>, <z:hpo ids='HP_0002910'>Elevated Liver enzymes</z:hpo>, <z:hpo ids='HP_0001873'>Low Platelet count</z:hpo>) syndrome and <z:mp ids='MP_0005048'>thrombosis</z:mp> that may be part of a catastrophic <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (CAPS) </plain></SENT>
<SENT sid="3" pm="."><plain>A previous <z:mp ids='MP_0005048'>thrombosis</z:mp> and the presence of a <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> are risk factors for pregnancy failure </plain></SENT>
<SENT sid="4" pm="."><plain>A multidisciplinary approach, associating the internist, the anesthesiologist and the obstetrician, is recommended for these <z:e sem="disease" ids="C0242786" disease_type="Disease or Syndrome" abbrv="">high-risk pregnancies</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Preconception counseling is proposed to identify pregnancy contraindications, and to define and adapt the treatment prior and during the upcoming pregnancy </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> and low-dose aspirin are the main treatments </plain></SENT>
<SENT sid="7" pm="."><plain>The choice between therapeutic or prophylactic doses of <z:chebi fb="5" ids="28304">heparin</z:chebi> will depend on the patient's medical history </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapeutic window for delivery should be as narrow as possible and adapted to maternal thrombotic risk </plain></SENT>
<SENT sid="9" pm="."><plain>There is a persistent maternal risk in the postpartum period (<z:mp ids='MP_0005048'>thrombosis</z:mp>, <z:e sem="disease" ids="C0162739" disease_type="Disease or Syndrome" abbrv="HELLP">HELLP syndrome</z:e>, CAPS) justifying an antithrombotic coverage during this period </plain></SENT>
<SENT sid="10" pm="."><plain>We suggest a monthly clinical and biological monitoring which can be more frequent towards the end of pregnancy </plain></SENT>
<SENT sid="11" pm="."><plain>The persistence of notches at the Doppler-ultrasound evaluation seems to be the best predictor for a higher risk of placental vascular complications </plain></SENT>
<SENT sid="12" pm="."><plain>Treatment optimization and multidisciplinary antenatal care improve the prognosis of pregnancies in women with obstetric APS, leading to a favorable outcome most of the time </plain></SENT>
</text></document>